The iTRAQ-based quantitative analysis showed that CDH18 was downregulated in tumor tissue from patients with glioma, and its downstream target, UQCRC2, was down-regulated in tumor tissue from patients with glioma compared to healthy tissue (80). Here, UQCRC2 is linked to neoplasm.